Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.92 USD
Change Today +0.03 / 1.04%
Volume 806.1K
IDRA On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

167 Sidney Street

Cambridge, MA 02139

United States

Phone: 617-679-5500

Fax: 617-679-5592

Idera Pharmaceuticals, Inc., a clinical stage biotechnology company, advances drug candidates for the treatment of autoimmune diseases and for certain genetically defined forms of B-cell lymphoma. These drug candidates are designed to inhibit over-activation of specific Toll-like receptors (TLRs). In addition to this TLR program, the company has initiated a research program employing its gene silencing oligonucleotides (GSOs), to inhibit the production of disease-associated proteins by targeting RNA. Programs for the Inhibition of Specific TLRs The company’s primary drug candidate in its TLR program is IMO-8400, an antagonist of TLR7, TLR8, and TLR9. IMO-8400 is in clinical development for the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma. The company is also conducting preclinical studies of IMO-9200, a second antagonist of TLR7, TLR8, and TLR9, to support the submission of an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA). A TLR antagonist is a compound that blocks activation of an immune response through the targeted TLR. Program in Autoimmune Diseases: The company achieved clinical proof-of-concept for its approach of inhibition of over-activation of specific TLRs for the treatment of psoriasis and potentially other autoimmune diseases based on the results of its Phase 2 clinical trial of IMO-3100, a TLR7 and TLR9 antagonist, in patients with moderate to severe psoriasis. The company is focusing clinical development in its autoimmune disease program on IMO-8400, as it targets TLR8 in addition to TLR7 and TLR9. It has completed a Phase 1 clinical trial of IMO-8400 in 42 healthy subjects, in which IMO-8400 was well tolerated and showed inhibition of TLR7, TLR8, and TLR9. In 2013, it completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 clinical trial that the company is conducting to evaluate the safety, tolerability and clinical activity of IMO-8400 through a 12-week treatment period in patients with moderate to severe plaque psoriasis. Program in Autoimmune Diseases with Orphan Indications: The company is planning to initiate clinical development of IMO-8400 and IMO-9200 for the treatment of autoimmune diseases with orphan indications. It has selected polymyositis and dermatomyositis as the first two orphan indications for which the company plans to develop IMO-8400. Program in Genetically Defined Forms of B-cell Lymphoma: The company’s internal studies using IMO-8400, which inhibits TLR7-, TLR8- and TLR9-mediated activity, have shown similar results of inducing cell death in tumor cells harboring the MYD88 L265P oncogenic mutation. The company initiated clinical development of IMO-8400 in patients with diffuse large B-cell lymphoma (DLBCL) by submitting a protocol for a Phase 1/2 clinical trial to the FDA in March 2014. Collaborative Alliances The company has a license and research collaboration agreement with Merck & Co. to research, develop and commercialize vaccine products containing its TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases and Alzheimer’s disease. Under the terms of the agreement, the company granted Merck & Co. worldwide exclusive rights to a number of its TLR7, TLR8, and TLR9 agonists for use in combination with Merck & Co.’s therapeutic and prophylactic vaccines under development in the fields of cancer, infectious diseases, and Alzheimer’s disease. Business Strategy The company’s business strategy is to develop IMO-8400, IMO-9200, and other TLR antagonist candidates for the treatment of autoimmune diseases with orphan indications and for the treatment of certain genetically defined forms of B-cell lymphomas. An element of its business strategy includes entering into collaborative alliances with corporate collaborators, primarily large pharmaceutical companies, for the development, commercialization, marketing, and distribution of its TLR antagonist candidates in broader autoimmune disease indications, such as psoriasis, lupus, and arthritis. Research and Development For the year ended December 31, 2013, the company spen

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDRA:US $2.92 USD +0.03

IDRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDRA.
View Industry Companies

Industry Analysis


Industry Average

Valuation IDRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,853.0x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,778.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IDERA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at